Clinical Trial Update: Study Evaluating MOA-728 Oral for the Treatment of OIBD in Subjects With Chronic Non-Malignant Pain [Phase 2]

View source ↗

Summary

Phase 2 trial update for MOA-728 oral in chronic non-malignant pain–associated opioid-induced bowel dysfunction (OIBD) completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Constipation

Drugs mentioned

• MOA-728

Snippet

Sponsor: Bausch Health Americas, Inc. | Conditions: Constipation | Phase 2 | Status: COMPLETED | Results posted: 2020-08-20